4,397 reports of this reaction
4.4% of all RIOCIGUAT reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for RIOCIGUAT, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 4,397 FDA adverse event reports linking RIOCIGUAT to HEADACHE. This represents approximately 4.4% of all 100,865 adverse event reports for this drug.
RIOCIGUAT has an overall safety score of 85 out of 100. Patients taking RIOCIGUAT who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among RIOCIGUAT users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for RIOCIGUAT:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 4,397 FDA reports for RIOCIGUAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.4% of all adverse event reports for RIOCIGUAT, making it one of the most commonly reported side effect.
If you experience headache while taking RIOCIGUAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.